HIGHLIGHTS
- who: Mitochondrial Modulator and collaborators from the Torrent Ltd, Ahmedabad, India University of Siena, Italy have published the Article: Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial, in the Journal: (JOURNAL)
- what: This paper describes the results of two Phase-1 studies, single ascending dose (SAD) and multiple ascending dose (MAD), conducted for evaluating the safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) parameters of TRC150094 ranging from 5 to 400 mg in overweight/obese subjects. The study protocols were reviewed and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.